The Zhitong Finance App learned that as competition between the two pharmaceutical giants continues to escalate, Novo Nordisk (NVO.US) has filed a lawsuit in the US federal court, accusing LLY.US (LLY.US) of misleading advertisements for its best-selling diet drug Zepbound and the diabetes injectable drug Mounjaro.

Zhitongcaijing · 2d ago
The Zhitong Finance App learned that as competition between the two pharmaceutical giants continues to escalate, Novo Nordisk (NVO.US) has filed a lawsuit in the US federal court, accusing LLY.US (LLY.US) of misleading advertisements for its best-selling diet drug Zepbound and the diabetes injectable drug Mounjaro.